Official Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
Brief Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.

Terminated
COVID-19

Drug: Placebo

Placebo administered BID approximately 12 hours apart

Drug: Ruxolitinib

Ruxolitinb administered BID approximately 12 hours apart
Other Name: Array

Eligibility Criteria

Inclusion Criteria:

- Participant or guardian health proxy must provide informed consent before any study
assessment is performed.

- Male or female participants aged ≥ 12 years.

- Participants with coronavirus (SARS-CoV-2) infection confirmed ≤ 3 weeks prior to
randomization by any test with local regulatory approval.

- Participants who are intubated and receiving mechanical ventilation due to
COVID-19-associated ARDS and have a PaO2/FiO2 of ≤ 300 mmHg within 6 -hours of
randomization.

Participants with lung imaging showing bilateral or diffuse pulmonary infiltrates on chest
x-ray or CT scan.

Exclusion Criteria:

- Known history of hypersensitivity to any drugs or metabolites of similar chemical
classes as ruxolitinib.

- Presence of severely impaired renal function defined by estimated creatinine clearance
< 15 mL/min measured or calculated by Cockcroft-Gault equation or calculated by the
updated bedside Schwartz equation. Participants must not be receiving CRRT or
intermittent hemodialysis at screening.

- In the opinion of the investigator, unlikely to survive for > 24 hours from
randomization.

- Suspected active uncontrolled bacterial, fungal, viral, or other infection (besides
COVID-19).

- Currently receiving ECMO.

- Participant may not be sharing a ventilator, or co-ventilating, with any other
patient.

- Treatment with anti-IL-6, IL-6R, IL-1RA, IL-1β, or GM-CSF antagonists, or a BTK
inhibitor, within 7 days of randomization.

- Treatment with a JAK inhibitor within 30 days of randomization.

- Participants who are on long-term use of antirejection or immunomodulatory drugs.

- Pregnant or nursing (lactating) women.

Eligibility Gender
All
Eligibility Age
Minimum: 12 Years ~ Maximum: N/A
Countries
Russian Federation
United States
Locations

Honor Health Research Institute
Scottsdale, Arizona, United States

Sharp Memorial Hospital
San Diego, California, United States

Georgetown University Hospital
Washington, District of Columbia, United States

Teradan Clinical Trials
Brandon, Florida, United States

University of Florida
Gainesville, Florida, United States

Tampa General Hospital
Tampa, Florida, United States

University of South Florida
Tampa, Florida, United States

Northshore University Health System
Chicago, Illinois, United States

Loyola University Medical Center
Maywood, Illinois, United States

Indiana University Simon Cancer Center
Indianapolis, Indiana, United States

Indiana University Health Central Indiana Cancer Centers
Indianapolis, Indiana, United States

East Jefferson General Hospital
Metairie, Louisiana, United States

Johns Hopkins University
Baltimore, Maryland, United States

Boston Medical Center
Boston, Massachusetts, United States

Lahey Hospital & Medical Center
Burlington, Massachusetts, United States

University of Massachusetts Medical School
Worcester, Massachusetts, United States

Healthpartners Cancer Care Center - Regions Hospital
Saint Paul, Minnesota, United States

Mercy Research
Springfield, Missouri, United States

Hackensack University Medical Center
Hackensack, New Jersey, United States

Rutgers Njms Clinical Research Unit
Newark, New Jersey, United States

Holy Name Medical Center
Teaneck, New Jersey, United States

University of Rochester Medical Center
Rochester, New York, United States

Duke University Medical Center
Durham, North Carolina, United States

East Carolina University
Greenville, North Carolina, United States

University of Cincinnati
Cincinnati, Ohio, United States

Kettering Cancer Care
Dayton, Ohio, United States

Jefferson University Hospitals
Philadelphia, Pennsylvania, United States

Temple University
Philadelphia, Pennsylvania, United States

West Penn Hospital
Pittsburgh, Pennsylvania, United States

Allegheny Health Network
Wexford, Pennsylvania, United States

St David'S Medical Center
Austin, Texas, United States

University of Texas Health Science Center At Houston - McGovern Medical School
Houston, Texas, United States

University of Texas Health Science Cente
San Antonio, Texas, United States

Wenatchee Valley Hospital and Clinics
Wenatchee, Washington, United States

Aurora Research Institute
Milwaukee, Wisconsin, United States

Sbih City Hospital 15
Saint Petersburg, Russian Federation

Incyte Corporation
NCT Number
Keywords
Cytokine storm
Covid-19
ARDS
SARS-CoV-2
ruxolitinib
Pneumonia
MeSH Terms
COVID-19
Janus Kinase Inhibitors